Hypermobility: hEDS, hypermobility spectrum disorders and the EDS family
Bendy joints are common, mostly harmless and occasionally the visible tip of a dangerous collagen gene. hEDS is the commonest named type, yet it is the only one with no gene, criteria that are being rewritten, and an internet reputation that has outrun the evidence. The useful clinical job is twofold: spot the rare vascular patient who must not be missed, and give everyone else a diagnosis, strength work and fewer opioids.
At a glance
- Hypermobility alone isn't a disease: generalised joint hypermobility (GJH) is reported in 6–57% of females and 2–35% of males depending on age, ethnicity and cut-off (Van Damme 2022).
- hEDS is a clinical diagnosis: all 3 criteria of the 2017 classification (Malfait 2017). Everyone else with symptomatic hypermobility has a hypermobility spectrum disorder (HSD), which is not "milder".
- No gene yet: sequencing of 1,000 people with hEDS found no single causal gene (HEDGE, 2025). KLK15 is a research lead, not a test.
- Don't miss vascular EDS (COL3A1): 25% have a first arterial or organ complication by 20 and over 80% by 40 (Pepin 2000). Arterial rupture, bowel or uterine rupture, or a family sudden death means genetics referral.
- Associations are real but oversold: ADHD, autism, anxiety and gut symptoms are linked; POTS overlaps in clinics; ASCIA 2025 says there is no evidence linking EDS or POTS to mast cell dysregulation.
Biggest take-home: screen for vascular red flags once, then treat function. Strength and proprioceptive training, pacing and pain education beat a hunt for the perfect label or a fourth opioid.
For patients: Ehlers-Danlos syndromes and hypermobility, POTS, MCAS and Chronic pain. For clinicians: the POTS and ME/CFS deep dives.
Definition
- Generalised joint hypermobility (GJH): Beighton score ≥6 in prepubertal children and adolescents, ≥5 in pubertal men and women to age 50, ≥4 over 50. One point below the cut-off still counts if 2 or more of the 5-part questionnaire items are positive (Malfait 2017).
- Beighton score (0–9): little finger dorsiflexion >90° (each side), thumb to forearm (each side), elbow hyperextension >10° (each side), knee hyperextension >10° (each side), palms flat on the floor with knees straight (1 point).
- Ehlers–Danlos syndromes (2017): 13 types from 19 genes; every type except hEDS needs a causative variant for a definite diagnosis. A 14th, classical-like type 2 (AEBP1), followed in 2018 (Malfait 2020).
- hEDS: Criterion 1 (GJH) + Criterion 2 (at least 2 of features A, B, C) + Criterion 3 (exclusions). Details in Diagnosis essentials.
- Hypermobility spectrum disorders (Castori 2017): symptomatic hypermobility not fitting another syndrome. Generalised (positive Beighton plus musculoskeletal problems), peripheral (hands and feet), localised (single joints or regions) and historical (past hypermobility, Beighton now negative).
- Asymptomatic hypermobility sits outside HSD: flexible and well is not a diagnosis.
History
- 1892, Russia: dermatologist A.N. Tschernogubow gave the first comprehensive description of lax skin and joints.
- 1901 and 1908: Danish dermatologist Edvard Ehlers and French dermatologist Henri-Alexandre Danlos described the skin and joint picture; Danlos stressed skin extensibility and fragility. Frederick Parkes Weber proposed "Ehlers–Danlos syndrome" in 1936.
- 1964: Carter and Wilkinson's joint laxity score, linked to congenital hip dislocation, the parent of the Beighton score.
- 1973, Phokeng, South Africa: Peter Beighton, Solomon and Soskolne modified it to 9 points while surveying 1,081 people in a Tswana village; females were more mobile than males at every age.
- 1998–2000: the Villefranche nosology (Beighton, De Paepe and colleagues) set 6 EDS types; Rodney Grahame, Howard Bird and Alan Child's Brighton criteria defined "benign joint hypermobility syndrome".
- 2010, Japan: Tomoki Kosho, Noriko Miyake and colleagues linked musculocontractural EDS to CHST14.
- 2017, international consortium: led by Fransiska Malfait (Ghent) with Marina Colombi, Clair Francomano, Cecilia Giunta, Hanadi Kazkaz and others: 13 types, tighter hEDS criteria and the new HSD label.
- 2024–2026: KLK15 reported in hEDS families (Gensemer 2025); HEDGE finds no single gene; revised criteria are due from December 2026.
Pathophysiology
For the genetic types, the pathway runs from gene to faulty collagen or matrix processing. For hEDS and HSD the mechanism is unknown; what follows are findings, not a model.
- Genetic EDS types: classical COL5A1/COL5A2 (variant found in over 90%); vascular COL3A1; arthrochalasia COL1A1/COL1A2 (exon 6 loss); dermatosparaxis ADAMTS2; cardiac-valvular COL1A2 (biallelic null); kyphoscoliotic PLOD1 or FKBP14; classical-like TNXB; myopathic COL12A1; spondylodysplastic B4GALT7, B3GALT6, SLC39A13; musculocontractural CHST14 or DSE; brittle cornea ZNF469 or PRDM5; periodontal C1R/C1S gain of function.
- Inheritance: autosomal dominant for classical, vascular, hypermobile, arthrochalasia and periodontal; autosomal recessive for most of the rest. Myopathic can be either.
- hEDS genetics: HEDGE: rare TNXB variants 3–5 times more common in hEDS but present in only about 1%; no MTHFR link. A GWAS preprint (1,815 cases) found 2 loci, one near ACKR3, with genetic correlations to ME/CFS, fibromyalgia, migraine and autism (Petrucci-Nelson 2025).
- Tissue: hEDS and HSD fibroblasts share a myofibroblast-like phenotype driven by αvβ3 integrin signalling, suggesting a continuum (Zoppi 2018; cell studies).
- Proprioception: worse knee and ankle joint position sense and movement detection than controls (meta-analysis, 5 studies, n=254; Smith 2013).
- Muscle and function: strength correlates with chair-rise (r=0.67) and 6-minute walk (r=0.58) in hEDS (Scheper 2017), the rationale for strength-based rehabilitation.
- Pain and disability: disability tracks fatigue (r=0.91), psychological distress (r=0.86) and pain (r=0.64) more than joint laxity (meta-analysis, Scheper 2016).
Epidemiology
- Self-reported hypermobility: 18.3% of 12,853 UK adults; linked only modestly to severe chronic widespread pain (adjusted RRR 1.6; Mulvey 2013).
- Children: 26.5% of Dutch 4–9-year-olds vs 5.3% of 10–12-year-olds at Beighton ≥4 (van der Giessen 2001); 4.6% of UK 14-year-olds at ≥6 (ALSPAC, Tobias 2013).
- Australia: in 1,000 people aged 3–101, females and non-Caucasians scored higher; a fixed cut-off of ≥4 suited only women aged 40–59 and men aged 8–39, so the authors proposed age- and sex-specific cut-offs (Singh 2017).
- Diagnosed EDS or HSD: 194 per 100,000 in Wales (about 1 in 500), 70% women; roughly 10 patients per 5,000-patient practice (Demmler 2019). Denmark: 0.02%, 74% female (Kulas Søborg 2017).
- Rare types: vascular EDS about 1 in 50,000–200,000 (Byers 2017); classical EDS about 1 in 20,000 (GeneReviews).
- Overlaps (mostly selected samples): 31% of 91 POTS patients met hEDS criteria (Miller 2020); 33% of 552 new gastroenterology referrals had joint hypermobility syndrome (Fikree 2014); adults with ADHD had GJH aOR 4.7 (Glans 2021); 51% of neurodivergent adults were hypermobile vs 20% expected (Csecs 2022).
- Diagnostic delay: mean 22 years for hEDS in a global survey of 3,906 (Daylor 2025); median 10 years in a Miami registry (Wang 2024). Surveys are self-selected.
Causes and risk factors
- Age and sex: mobility falls quickly through childhood and more slowly in adults; females are more mobile at every age (Beighton 1973).
- Ancestry: higher Beighton scores in some non-European groups, so a single cut-off misclassifies (Remvig 2007; Singh 2017).
- Family: hEDS is presumed autosomal dominant; an affected first-degree relative is Feature B. Siblings of people with EDS have raised ADHD risk (RR 2.1; Cederlöf 2016).
- Mimics: neuromuscular disorders, other heritable connective tissue disorders and skeletal dysplasias must be excluded before calling it hEDS (Criterion 3). Marfanoid habitus or lens dislocation needs genetics review (AJGP 2022).
- Obesity: in hypermobile adolescents, knee pain odds were 11.0 with obesity vs 1.57 without (ALSPAC; Tobias 2013).
Preventable factors
- Deconditioning: strength and endurance underpin function (Scheper 2017); long rest after injury is the enemy.
- Weight: the ALSPAC obesity interaction is the clearest modifiable risk for knee pain in hypermobile teenagers.
- Iatrogenic harm: 62% of US adults with EDS used opioids vs 34% of controls, with higher cumulative doses (Schubart 2019). Only 34% of operated hEDS patients rated surgery positively (Rombaut 2011).
- Vascular EDS events: treat hypertension aggressively, avoid invasive arterial procedures where possible, carry an emergency letter, centralise care (Byers 2017).
- Missed diagnosis: delays of 10–22 years mean years without explanation or rehabilitation.
Diagnosis essentials
- Step 1, red flags (once, early): arterial rupture or dissection before 40, sigmoid perforation without diverticular disease, third-trimester uterine rupture, carotid-cavernous fistula, family history of sudden death, thin translucent skin, easy bruising, pneumothorax. These point to vascular EDS: refer to clinical genetics (Malfait 2017; Byers 2017).
- Other referral triggers (AJGP 2022): any cardiovascular involvement (echo and genetics urgently), aortic dilatation, wide atrophic scars, poor wound healing, blue sclerae, lens dislocation or high myopia, marfanoid habitus, cleft palate or bifid uvula, recurrent hernia or pneumothorax, ≥2 low-force fractures, severe scoliosis.
- Criterion 1: Beighton by the age cut-offs; the 5-part questionnaire (any 2 of 5 positive) had 84% sensitivity and 80–89% specificity (Hakim and Grahame 2003). Beighton interrater reliability is substantial in about 60% of studies (Bockhorn 2021).
- Criterion 2, feature A (≥5 of 12): soft skin, mild skin hyperextensibility, unexplained striae, bilateral heel piezogenic papules, recurrent hernias, atrophic scars at ≥2 sites, prolapse in children, men or nulliparous women, dental crowding with high palate, arachnodactyly (wrist and thumb signs), arm span:height ≥1.05, mitral valve prolapse, aortic root Z-score >+2.
- Feature B: a first-degree relative who independently meets hEDS criteria. Feature C (≥1): pain in ≥2 limbs daily for ≥3 months; chronic widespread pain ≥3 months; or recurrent atraumatic dislocations or confirmed instability.
- Criterion 3: no unusual skin fragility; other heritable and acquired connective tissue disorders and alternative diagnoses excluded. With an autoimmune rheumatic disease, features A and B are required.
- Tests: there is no hEDS gene test, and NSW public genetics services say referral is "usually not indicated" for hEDS alone (RPA). Panels only when features suggest another type.
- Look for, don't assume: active stand test for orthostatic symptoms; ASCIA 2025: MCAS needs all 3 consensus criteria, and EDS or POTS "should not be used as part of the criteria to diagnose MCAS".
Current treatment
No drug treats hEDS or HSD. The evidence for rehabilitation is small, short and mostly in women; it is still the best we have.
Rehabilitation
- Exercise overall: 11 studies of conservative care, all exercise-based; consistent pre-post gains but only 3 small controlled studies beat control (Palmer 2021). An earlier review found "no convincing evidence" exercise beats control (Palmer 2014).
- Systematic review 2022: 10 studies, 330 participants, 5 RCTs; all showed some physical or psychological improvement; one non-serious adverse event (Buryk-Iggers 2022).
- Children (Sydney RCT, n=26): 8 weeks of knee strengthening cut maximal knee pain by 14.5 mm on a 100 mm VAS whether exercising into the hypermobile range or only to neutral (Pacey 2013).
- Targeted vs general physiotherapy (n=57 children): pain improved in both, with no difference (Kemp 2010).
- Compression garments (RCT, n=36 hEDS): added to physiotherapy, improved dynamic balance (sway velocity effect size 0.93); pain fell equally in both arms (Benistan 2024).
- Inspiratory muscle training: 77% had low inspiratory strength; 6 weeks of training raised 6-minute walk by 60 m (Reychler 2019).
- Physio plus CBT: a 12-woman pilot improved daily activity, strength and kinesiophobia, with smaller pain change (Bathen 2013).
Pain, fatigue and the rest
- Pain: about 90% report chronic pain (Chopra 2017). Pain education, graded activity with pacing, bracing or taping for unstable joints; avoid opioids and use NSAIDs cautiously (AJGP 2022).
- Psychology: anxiety is common (meta-analysis OR 4.39; Smith 2014); CBT or ACT for pain coping and kinesiophobia, never as a suggestion the symptoms are imagined.
- Orthostatic symptoms: fluids, salt and compression first; medicines for moderate to severe cases (Hakim 2017). See the POTS deep dive.
- Gut: treat as disorders of gut–brain interaction with standard therapy; the AGA 2025 update does not support routine POTS or MCAS testing (Aziz 2025).
- Surgery: only 34% of operated hEDS patients reported a positive outcome (Rombaut 2011). Exhaust rehabilitation first; warn about wound healing and local anaesthetic failure, which has been reported (Hakim 2005).
- Vascular EDS: celiprolol (up to 400 mg/day) cut arterial events from 50% to 20% (HR 0.36; BBEST, Ong 2010, open-label, n=53); survival was better on celiprolol in an observational cohort of 144 (Frank 2019). Yearly arterial imaging, emergency letter, specialist centre (Byers 2017).
Pregnancy
- hEDS/HSD: Swedish register (314 births): no increase in preterm birth, caesarean or stillbirth; more induction in EDS (Sundelin 2017). A self-selected online survey reported higher rates (preterm 25%; Hurst 2014).
- All EDS (US inpatient data): cervical insufficiency aOR 3.11, prematurity aOR 1.47 (Spiegel 2022).
- Vascular EDS: 5.3% of deliveries in pedigrees ended in maternal death; life-threatening complications in 14.5% (Murray 2014). Pre-pregnancy counselling and shared decisions in a specialist centre.
Emerging treatments and trials
- DiSCOVER (NCT05432466): phase 3, double-blind celiprolol vs placebo in COL3A1-positive vascular EDS; target 150, event-driven; enrolling (Zevra).
- Enzastaurin in vascular EDS (NCT05463679): phase 3 planned for 260, suspended in 2022 for financial reasons.
- New criteria: a criteria study of 326 adults at 8 sites in 6 countries found no single feature that separates hEDS from HSD. The first update since 2017 starts in the American Journal of Medical Genetics on 2 December 2026; the hEDS/HSD criteria are now expected March–April 2027 (Ehlers-Danlos Society).
- KLK15: a recurrent p.Gly226Asp variant segregated in families and a knock-in mouse showed tendon and valve changes (Gensemer 2025). The Society says it is "too soon" for testing.
- Rehabilitation trials: compression garments and inspiratory muscle training have small positive RCTs; larger, longer whole-body programmes are the gap every review names.
Theoretical frontiers
Hypotheses, not recommendations.
Causes: theories
- Hypothesis: hEDS is polygenic, with KLK-family variants as one contributor. For: KLK15 segregation and mouse phenotype (Gensemer 2025); 2 GWAS loci (Petrucci-Nelson 2025). Against: single lab; HEDGE found no single gene in 1,000. Test: independent replication and functional work in other cohorts.
- Hypothesis: tenascin-X loss explains a small subset. For: rare TNXB variants 3–5 times more common in hEDS (HEDGE); TNXB heterozygote females can have GJH. Against: present in only about 1%. Test: TNXB-stratified natural history studies.
- Hypothesis: hEDS and HSD are one continuum. For: shared fibroblast phenotype (Zoppi 2018); the criteria study found no separating feature. Against: cell studies are small; families with clear dominant inheritance suggest a distinct group. Test: validation of the 2027 criteria against genetic and outcome data.
- Hypothesis: shared biology with neurodivergence and nociplastic pain. For: autism RR 7.4 and ADHD RR 5.6 in EDS (Cederlöf 2016); GWAS genetic correlations with ME/CFS, fibromyalgia and autism. Against: ascertainment bias and register coding. Test: population cohorts with blinded Beighton scoring and genotyping.
- Hypothesis: mast cells drive the symptom cluster. For: retrospective MCAS codes in 31% of POTS+EDS patients (Wang 2021). Against: ASCIA 2025; hereditary α-tryptasaemia not increased in 266 people with hypermobility (Vazquez 2022). Test: prospective controlled study using consensus MCAS criteria.
Prevention: theoretical options
- Hypothesis: strength training in hypermobile children prevents adult pain. For: hypermobility at 14 predicted pain at 18 (Tobias 2013); short-term paediatric RCT benefit (Pacey 2013). Against: no prevention trial. Test: school-based cluster RCT with 5-year pain outcomes.
- Hypothesis: weight control prevents hypermobile knee pain. For: knee pain OR 11.0 with obesity vs 1.57 without. Against: observational. Test: weight intervention trials in hypermobile adolescents.
- Hypothesis: early diagnosis cuts disability. For: delays of 10–22 years; UK survey 45.6% unemployed (Berg 2026). Against: no evidence that earlier labels change outcomes. Test: stepped-wedge primary care diagnostic pathway study.
- Hypothesis: opioid stewardship prevents iatrogenic decline. For: opioid use 62% vs 34% (Schubart 2019). Against: no outcome data. Test: registry comparison of opioid-sparing pain programmes.
Treatment: theoretical options
- Hypothesis: proprioceptive aids improve function. For: compression garments improved balance (Benistan 2024). Against: 4 weeks, n=36, no pain difference. Test: longer RCT with falls and function end points.
- Hypothesis: combined physio and psychology outperforms either alone. For: disability tracks fatigue and distress more than laxity (Scheper 2016); Bathen pilot. Against: uncontrolled, n=12. Test: factorial RCT.
- Hypothesis: respiratory muscle training reduces fatigue. For: 60 m gain in 6-minute walk (Reychler 2019). Against: single trial. Test: blinded sham-controlled RCT.
- Hypothesis: genotype-directed therapy. For: a dominant-negative KLK15 mechanism is proposed. Against: nothing yet in humans. Test: target validation in the mouse model.
- Hypothesis: vascular EDS events are preventable with drugs. For: BBEST and the Frank cohort. Against: open-label, small. Test: DiSCOVER.
Gaps and open questions
- No gene, shifting criteria: hEDS remains a clinical diagnosis until replication succeeds; 2027 criteria will change who qualifies.
- No guideline: the British Society for Rheumatology declined to write one in 2020 because the evidence base was insufficient; no NICE or Australian guideline exists.
- Weak trials: small, short, single-region and mostly women; no long-term follow-up (Palmer 2021).
- Cut-offs: Beighton thresholds misclassify by age, sex and ancestry; measurement studies were rated "fair" or "poor" (Juul-Kristensen 2017).
- Associations: POTS, MCAS and gut figures come from referral clinics; MCAS rates vary from 2% to 87% depending on criteria (Yao 2025).
- Equity: almost no data for Aboriginal and Torres Strait Islander people, rural Australians or low-income countries.
Prognosis and quality of life
- Quality of life: all 8 RAND-36 domains impaired in 32 women with hEDS vs controls (Rombaut 2010).
- Work: 31.6% of Danes with diagnosed EDS received state support, mostly early retirement pensions (Kulas Søborg 2017); 45.6% unemployed in a UK survey (Berg 2026).
- Comorbidity: anxiety OR 4.39, depression OR 4.10, panic OR 6.72 (Smith 2014); autism RR 7.4, ADHD RR 5.6, suicide attempt RR 2.1, no increase in suicide (Cederlöf 2016).
- Mortality: no hEDS-specific data. Vascular EDS median survival 48 years in 2000 and 51 years in a 2014 cohort of 1,231 (Pepin).
Weird trivia
- Born in a village survey: the Beighton score was first used on 1,081 people in Phokeng, a Tswana village near Johannesburg, in 1973.
- Gorlin sign: 8.2% of Dutch schoolchildren could touch their nose with their tongue (van der Giessen 2001).
- Heel bumps: piezogenic pedal papules on the heels were found in 10 of 29 people with EDS (Kahana 1987) and are a feature A item.
- Why zebras: the Ehlers-Danlos Society flips the teaching maxim: "Sometimes when you hear hoofbeats, it really is a zebra." The earliest printed "hoofbeats" saying traced is a 1962 Arkansas newspaper.
- Paganini's hands: JAMA papers have suggested a connective tissue disorder (1967) and Marfan syndrome (1978); nobody can settle it now.
- Rubber-skin acts: a 1908 New York Medical Journal report described a performer who could pull his forehead skin down over his face.
- Not MTHFR: the HEDGE sequencing study found no MTHFR link, despite its popularity online.
Guidelines
- Nicholson LL, Chan C, Tofts L, Pacey V. Hypermobility syndromes in children and adolescents. Aust J Gen Pract 2022
- ASCIA. Diagnosis and investigation of mast cell activation disorders and syndrome (updated December 2025)
- RPA Clinical Genetics (Sydney LHD). EDS and HSD referral guidance
- Malfait F et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C 2017
- Castori M et al. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C 2017
- Byers PH et al. Diagnosis, natural history and management in vascular EDS. Am J Med Genet C 2017
- Engelbert RHH et al. Physical therapy in hEDS and HSD. Am J Med Genet C 2017
- Chopra P et al. Pain management in the Ehlers–Danlos syndromes. Am J Med Genet C 2017
- Hakim A et al. Cardiovascular autonomic dysfunction in EDS-hypermobile type. Am J Med Genet C 2017
- Aziz Q et al. AGA clinical practice update on GI manifestations of hEDS and HSD. Clin Gastroenterol Hepatol 2025
- British Society for Rheumatology. Statement on hypermobility guidelines (2020)
Key trials
- BBEST (Ong 2010): celiprolol in vascular EDS, n=53, arterial events 20% vs 50%.
- DiSCOVER (ongoing): celiprolol vs placebo in vascular EDS, target 150.
- Pacey 2013: knee strengthening in hypermobile children, n=26, Sydney.
- Kemp 2010: targeted vs general physiotherapy in children, n=57.
- Benistan 2024: compression garments plus physiotherapy in hEDS, n=36.
- Reychler 2019: inspiratory muscle training in hEDS.
- HEDGE (2025): sequencing of 1,000 people with hEDS and 45 with HSD.
Sources
- Carter C, Wilkinson J. Persistent joint laxity and congenital dislocation of the hip. J Bone Joint Surg Br 1964
- Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973
- Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility. Int J Clin Pract 2003
- Juul-Kristensen B et al. Measurement properties of clinical assessment methods for joint hypermobility. Am J Med Genet C 2017
- Bockhorn LN et al. Interrater and intrarater reliability of the Beighton score. Orthop J Sports Med 2021
- Singh H et al. Reference values for the Beighton score in Australians aged 3–101. Rheumatology 2017
- Van Damme T et al. The Ehlers–Danlos syndromes against the backdrop of inborn errors of metabolism. Genes 2022
- Malfait F et al. The Ehlers–Danlos syndromes. Nat Rev Dis Primers 2020
- Blackburn PR et al. Bi-allelic AEBP1 variants cause a new EDS-like syndrome. Am J Hum Genet 2018
- Ehlers-Danlos Society. 2017 EDS classification summary
- Ehlers-Danlos Society. hEDS diagnostic checklist
- Forghani I. Updates in clinical and genetics aspects of hypermobile EDS. Balkan Med J 2019
- Parapia LA, Jackson C. Ehlers–Danlos syndrome: a historical review. Br J Haematol 2008
- Beighton P et al. Ehlers–Danlos syndromes: revised nosology, Villefranche 1997. Am J Med Genet 1998
- Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for benign joint hypermobility syndrome. J Rheumatol 2000
- Miyake N, Kosho T et al. Loss-of-function mutations of CHST14 in a new type of EDS. Hum Mutat 2010
- Pepin M et al. Clinical and genetic features of EDS type IV, the vascular type. N Engl J Med 2000
- Pepin MG et al. Survival is affected by mutation type and molecular mechanism in vascular EDS. Genet Med 2014
- Gensemer C et al. KLK15 variants in hypermobile EDS. iScience 2025
- Ehlers-Danlos Society. KLK15 genetic testing update (2024)
- Ehlers-Danlos Society. HEDGE study update (2025)
- Petrucci-Nelson T et al. Genome-wide association study of hEDS. medRxiv 2025 (preprint)
- Zoppi N et al. Dermal fibroblast-to-myofibroblast transition in hEDS and HSD. Biochim Biophys Acta Mol Basis Dis 2018
- Ehlers-Danlos Society. hEDS/HSD criteria review study update
- Ehlers-Danlos Society. New global diagnostic criteria (updated November 2026)
- Smith TO et al. Do people with benign joint hypermobility syndrome have reduced joint proprioception? Rheumatol Int 2013
- Scheper MC et al. The association between muscle strength and activity limitations in hEDS. Disabil Rehabil 2017
- Scheper MC et al. Disability in adults with generalized joint hypermobility: meta-analysis. Arch Phys Med Rehabil 2016
- Mulvey MR et al. Self-reported hypermobility and chronic widespread pain. Arthritis Care Res 2013
- Tobias JH et al. Joint hypermobility and musculoskeletal pain in adolescence (ALSPAC). Arthritis Rheum 2013
- van der Giessen LJ et al. Validation of the Beighton score in Dutch children. J Rheumatol 2001
- Remvig L et al. Epidemiology of general joint hypermobility. J Rheumatol 2007
- Demmler JC et al. Diagnosed prevalence of EDS and hypermobility spectrum disorder in Wales. BMJ Open 2019
- Kulas Søborg ML et al. Ehlers–Danlos syndrome in Denmark: nationwide register cohort. Rheumatology 2017
- GeneReviews. Classic Ehlers–Danlos syndrome (updated 2024)
- Daylor V et al. Diagnostic delay in hEDS and HSD: global survey. J Clin Med 2025
- Wang E et al. Miami hEDS registry. Am J Med Genet A 2024
- Berg et al. Living with hEDS and HSD in the UK: survey. Disabil Rehabil 2026
- Cederlöf M et al. Psychiatric disorders in EDS and hypermobility syndrome: Swedish register study. BMC Psychiatry 2016
- Glans M et al. Joint hypermobility in adults with ADHD. J Psychiatr Res 2021
- Csecs JLL et al. Joint hypermobility links neurodivergence to dysautonomia and pain. Front Psychiatry 2022
- Smith TO et al. Anxiety and depression in joint hypermobility syndrome: meta-analysis. Rheumatology 2014
- Miller AJ et al. Prevalence of hEDS in POTS. Auton Neurosci 2020
- Yao et al. Joint hypermobility and MCAS in young people with POTS by different criteria. Front Neurol 2025
- Kucharik AH, Chang C. The relationship between hEDS, POTS and MCAS. Clin Rev Allergy Immunol 2020
- Wang E et al. MCAS in POTS and EDS: chart review. Allergy Asthma Proc 2021
- Vazquez M et al. Hereditary α-tryptasaemia in hypermobility disorders. HGG Adv 2022
- Fikree A et al. Joint hypermobility syndrome in gastroenterology referrals. Clin Gastroenterol Hepatol 2014
- Palmer S et al. Exercise therapy for joint hypermobility syndrome: systematic review. Physiotherapy 2014
- Palmer S et al. Conservative management of hEDS and HSD: systematic review. Clin Rheumatol 2021
- Buryk-Iggers S et al. Exercise and rehabilitation in hEDS and HSD: systematic review. Arch Rehabil Res Clin Transl 2022
- Pacey V et al. Exercise in children with joint hypermobility syndrome and knee pain: RCT. Pediatr Rheumatol 2013
- Kemp S et al. Targeted vs generalized physiotherapy in children with JHS: RCT. Rheumatology 2010
- Benistan K et al. Compression garments and physiotherapy in hEDS: RCT. Disabil Rehabil 2024
- Reychler G et al. Inspiratory muscle training in hEDS. Am J Med Genet A 2019
- Bathen T et al. Multidisciplinary treatment of disability in EDS hypermobility type. Am J Med Genet A 2013
- Rombaut L et al. Medication, surgery and physiotherapy in hEDS. Arch Phys Med Rehabil 2011
- Rombaut L et al. Impairment and impact of pain in female patients with EDS hypermobility type. Disabil Rehabil 2010
- Schubart JR et al. Use of prescription opioid and other drugs among people with EDS. Am J Med Genet A 2019
- Hakim AJ et al. Local anaesthetic failure in joint hypermobility syndrome. J R Soc Med 2005
- Bulbena A et al. Psychiatric and psychological aspects in the Ehlers–Danlos syndromes. Am J Med Genet C 2017
- Ong KT et al. Effect of celiprolol on cardiovascular events in vascular EDS (BBEST). Lancet 2010
- Frank M et al. Vascular EDS: long-term observational study. J Am Coll Cardiol 2019
- Zevra Therapeutics. DiSCOVER trial of celiprolol in vascular EDS
- Enzastaurin for prevention of arterial events in vascular EDS (NCT05463679)
- Sundelin HEK et al. Pregnancy outcomes in women with joint hypermobility syndrome and EDS. Acta Obstet Gynecol Scand 2017
- Spiegel E et al. Pregnancy outcomes in women with EDS. J Matern Fetal Neonatal Med 2022
- Hurst BS et al. Obstetric and gynecologic challenges in women with EDS. Obstet Gynecol 2014
- Murray ML et al. Pregnancy-related deaths and complications in women with vascular EDS. Genet Med 2014
- Kahana M et al. Painful piezogenic pedal papules in patients with EDS. J Am Acad Dermatol 1987
- Ehlers-Danlos Society. Why the zebra?
- Quote Investigator. When you hear hoofbeats, think of horses, not zebras
- Smith RD, Worthington JW. Paganini: the riddle and connective tissue. JAMA 1967
- Schoenfeld MR. Nicolo Paganini: musical magician and Marfan mutant? JAMA 1978
- Disability History Museum. "The elastic skin man" (New York Medical Journal, 1908)
- Ehlers-Danlos Society. Research priorities (2026)
Information only. Check product information, PBS criteria and current Australian guidelines before prescribing. No medicine is TGA-approved for hEDS or HSD; medicines above are used off-label.
maladywise.com/deep-dives/hypermobility/